A phase I clinical trial to evaluate the safety and immunogenicity of the HIV-1 DNA vaccine VRC-HIVDNA009-00-VP (gag-pol-nef-multiclade env) with the plasmid cytokine adjuvant VRC-ADJDNA004-IL2-VP (IL-2/Ig).

Trial Profile

A phase I clinical trial to evaluate the safety and immunogenicity of the HIV-1 DNA vaccine VRC-HIVDNA009-00-VP (gag-pol-nef-multiclade env) with the plasmid cytokine adjuvant VRC-ADJDNA004-IL2-VP (IL-2/Ig).

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2015

At a glance

  • Drugs VRC-HIVDNA009-00-VP (Primary) ; VRC-ADJDNA004-IL2-VP
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 03 May 2012 Actual end date changed from Aug 2009 to Dec 2006 as reported by ClinicalTrials.gov.
    • 21 Sep 2011 Results published in the Journal of Infectious Diseases.
    • 01 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top